US › Healthcare

Coya Therapeutics, Inc. Common Stock (COYA)

US · Healthcare · Biotechnology

$4.57+3.16%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$251,147
Revenue YoY
-2.6%
Net profit
$-7.2M
Profit YoY
+1.4%
EPS
$-0.32
EPS estimate
$-0.69
Net margin
-2,869.6%

EPS came in at -0.32 against a street estimate of -0.69 — a beat of 53.9%.

Key statistics

Market cap
$103.9M
Forward P/E
0.0
P/B
2.01
Book value
$2.09
EPS (TTM)
$-1.15
52-week high
$7.75
52-week low
$3.71
50-day MA
$4.86
200-day MA
$5.05
Beta
0.60

Analyst view

Analysts rate Coya Therapeutics, Inc. Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $15.21.

Shareholding

Insiders
14.69%
Institutions
35.66%

Largest institutional holders

FundStake
AIGH Capital Management, LLC4.16%
Vanguard Capital Management, LLC3.60%
Alyeska Investment Group, L.P.3.41%
Prosight Management, LP1.79%
CM Management, LLC1.60%
Private Management Group Inc1.57%
Geode Capital Management, LLC0.99%
Marshall Wace Asset Management Ltd0.96%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Coya Therapeutics, Inc. Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.